PETVIVO & SPRYNG™
PETVIVO & SPRYNG™
In the development of our long-term implants, Dr. Masters recognized the many advantages of matching the implants composition to the native tissue surrounding the implant site. Furthermore, Dr. Masters recognized that these biomatrix materials exhibited no adverse effects. Therefore, the Company, now a subsidiary of PetVivo, began pursuing the development of several new product lines that utilized the Company’s proprietary biomatrix materials. In an effort to scale manufacturing, the Company developed an improved manufacturing process in 2004, which also produced a superior biomaterial that inherently possessed thermoplastic properties.
Beginning in 2005 and continuing through 2013, the National Institutes of Health awarded the Company a series of grants totaling $5.5M for the development of vascular grafts and other devices. The work derived from the vascular graft grant produced the completion of pre-clinical testing required for a FDA small diameter vascular graft clinical trial.
safety and efficacy
The Company determined that the easiest path to validate the safety and efficacy of the Company’s new biomatrix implant material for human use was as a dermal filler. In 2006, the FDA approved the Company’s IDE to conduct a Randomized, Double-Blind, Multicenter Dermal Filler Clinical Trial. The Company’s CosmetaLife dermal filler was injected into one side of each trial participant’s face and Restylane (Control) was injected into the other side. The blinded participants scored each naso-labial fold using the Global Aesthetic Improvement Scale and preferred the Company’s product at all trial time points.
After eight years from the date of filing an application, the United States Patent and Trademark Office issued the Company US Patent 8,153,591, entitled “Protein “Biomaterials and Biocoacervates and Methods of Making and Using Thereof. Filed in 2004, this key patent included ninety-three claims focused on many aspects of our biomatrix materials, manufacturing processes and numerous methods of use.
To date, the Company has 18 issued U.S. and foreign patents and 10 pending patent applications. Moreover, the Company has developed a large pipeline of medical devices that contain our proprietary thermoplastic protein-based biomaterials. These therapeutic devices mimic the body’s tissue.
Spryng™ COMES TO MARKET
In 2017, PetVivo Holdings, Inc. completed a merger with Gel-Del Technologies, Inc., which is now a wholly owned subsidiary of the Company. Initially, we are commercializing our technology in the animal healthcare market for the treatment of osteoarthritis, but anticipate launching other veterinary and human products in the near-term.
Choose your path
Which path would you like to take?
Select the most fitting category for you below:
FREQUENTLY ASKED QUESTIONS
What is spryng™?
Spryng™ with OsteoCushion™ Technology is an IA injection of sterilized, hydrogel micro-particles that are wet, slippery and spongy. Our patented technology allows novel self-assembly of elastin, collagen and heparin to mimic cartilage extracellular matrix in both form and function. The Spryng™ particle components are natural, animal based, and tightly cross-linked together to form a strong matrix material that resists enzymatic degradation, inhibits immune cell recognition, and thus, avoids the need for allergy pretesting.
How does spryng™ work?
Spryng™ with OsteoCushion™ Technology uses precisely sized micro-particles for optimal joint spacing and for easy intra-articular injection with 18-23 gauge needles. Spryng™ particles are too large to seep through synovial membranes, allowing long duration of their slippery cushion effects to reinforce the joint's articular cartilage and ameliorate or preclude the cartilage defects that cause pain to limit motion.
How long does spryng™ last?
The demonstrated spryng™ effects are long-lasting. Veterinarians are reporting that the positive, cushioning effects typically last about 12 months, depending mostly on activity levels. The spryng™ particles gradually resorb into the surrounding synovial tissue.
Has spryng™ been studied?
Five plus years of spryng™ case studies provided positive veterinarian testimonials. No adverse effects have been observed or reported other than some mild, short-term injection site responses.
How can I get spryng™ for my animal?
Spryng™ with OsteoCushion™ Technology is available to your animal through certain licensed and certified veterinarians. To find a veterinarian in your area who can administer spryng™ to your animal, we are happy to help you locate one. Please email us at INFO1@PETVIVO.COM or you may fill out our contact form here.
What if I have more questions?
We're ready to answer and address any questions or concerns. Whether by phone, e-mail, mail, and more, you can contact our support team here.